Literature DB >> 32251795

Presepsin values as markers of severity of sepsis.

Ajete Aliu-Bejta1, Anita Atelj2, Mentor Kurshumliu3, Shemsedin Dreshaj4, Bruno Baršić5.   

Abstract

OBJECTIVES: Biomarkers are widely used for rapid diagnosis of sepsis. This study evaluated the diagnostic accuracy of presepsin, procalcitonin (PCT), and C-reactive protein (CRP) in differentiating sepsis severity as well as their association with Sepsis-related Organ Failure Assessment (SOFA) score.
METHODS: One hundred septic patients from two university clinical centers were enrolled in the study during two time periods. New Sepsis-3 definitions were used for sepsis stratification. Biomarkers and SOFA score were evaluated four times during the illness. A sandwich ELISA kit was used for presepsin measurement. Generalized linear mixed effects model was used to test the changes in biomarkers concentrations and SOFA score values during the illness and to estimate the differences between severity groups. Multivariate analysis was used to test the association of biomarkers with SOFA score.
RESULTS: Presepsin concentrations were significantly higher on admission in patients with septic shock (n = 34) compared to patients with sepsis (n = 66), mean ± SD: 128.5 ± 47.6 ng/mL vs. 88.6 ± 65.6 ng/mL, respectively (p < 0.001). The same was not observed for PCT and CRP; their concentrations did not differ significantly between severity groups. A strong correlation of presepsin with SOFA score was also found (p < 0.0001).
CONCLUSIONS: Presepsin had a good diagnostic ability to differentiate septic shock from sepsis in the study groups. PCT and CRP failed in differentiating sepsis severity.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  C-reactive protein; SOFA score; presepsin; procalcitonin; sepsis severity

Year:  2020        PMID: 32251795     DOI: 10.1016/j.ijid.2020.03.057

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  8 in total

1.  Diagnostic value of presepsin in odontogenic infection: a retrospective study.

Authors:  Eun-Sung Kang; Jae-Hoon Lee
Journal:  Maxillofac Plast Reconstr Surg       Date:  2022-06-06

Review 2.  [Which biomarkers for diagnosis and guidance of anti-infection treatment in sepsis?]

Authors:  Johannes Ehler; Christoph Busjahn; Tobias Schürholz
Journal:  Anaesthesist       Date:  2021-11-12       Impact factor: 1.041

Review 3.  Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review.

Authors:  Maria Sanz Codina; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2022-02-25       Impact factor: 5.577

4.  Performance of presepsin and procalcitonin predicting culture-proven bacterial infection and 28-day mortality: A cross sectional study.

Authors:  Jiho Park; Ji Hyun Yoon; Hyun Kyun Ki; Jae-Hoon Ko; Hee-Won Moon
Journal:  Front Med (Lausanne)       Date:  2022-08-22

Review 5.  Pathophysiology of Sepsis and Genesis of Septic Shock: The Critical Role of Mesenchymal Stem Cells (MSCs).

Authors:  Matthieu Daniel; Yosra Bedoui; Damien Vagner; Loïc Raffray; Franck Ah-Pine; Bérénice Doray; Philippe Gasque
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

Review 6.  Presepsin as a Diagnostic and Prognostic Biomarker in Sepsis.

Authors:  Dimitrios Velissaris; Nicholas Zareifopoulos; Vasileios Karamouzos; Evangelos Karanikolas; Charalampos Pierrakos; Ioanna Koniari; Menelaos Karanikolas
Journal:  Cureus       Date:  2021-05-13

Review 7.  Differential Markers of Bacterial and Viral Infections in Children for Point-of-Care Testing.

Authors:  Yu-Ting Tsao; Yao-Hung Tsai; Wan-Ting Liao; Ching-Ju Shen; Ching-Fen Shen; Chao-Min Cheng
Journal:  Trends Mol Med       Date:  2020-09-29       Impact factor: 11.951

8.  Evaluation of the Diagnostic and Prognostic Value of CSF Presepsin Levels in Patients with Postneurosurgical Ventriculitis/Meningitis.

Authors:  Guanghui Zheng; Chenxi Zhang; Guojun Zhang; Chunqing Shao
Journal:  Infect Drug Resist       Date:  2021-07-27       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.